Posted by Michael Wonder on 07 Feb 2022
NGM Bio’s NGM621 receives fast track designation from the FDA for the treatment of patients with geographic atrophy secondary to age-related macular degeneration
7 February 2022 - NGM Biopharmaceuticals today announced that the U.S. FDA has granted fast track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.
NGM Bio is currently evaluating NGM621 in its ongoing Phase 2 CATALINA study and a topline data readout is expected in the fourth quarter of 2022.
